Detail akcie GENinCode Rg online

Business Summary: GENinCode Plc is a United Kingdom-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer. Its testing products include CARDIO inCode Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA Test. Its SITAB is an online Web portal, which provides health care practitioners with a systemized approach to request, record, process and report their clinical and genetic test results. Its CARDIO inCode Score is a genetic test for the evaluation of the coronary genetic load based on a polygenic risk score.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Genincode PLC revenues increased 15% to L1.6M. Net loss increased 22% to L3M. Revenues reflect Spain segment increase of 15% to L1M, United Kingdom segment increase of 14% to L346K, US segment increase of 24% to L88K. Higher net loss reflects Medical Equipment segment loss increase of 20% to L3M. Basic Earnings per Share excluding Extraordinary Items remained flat at -L0.01.